Pathfinders in Biopharma

Nov 22 2024 45 ep. 21 mins 16
Pathfinders in Biopharma Podcast artwork

Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.

  Business  News
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments

Nov 22 2024 22 mins  
Innovation is surging in the U.S biotechnology sector, so why are investors still fearful about committing? Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, is joined by fund founders Craig Gordon, MD, CEO and CIO at GordonMD® Global Investments LP and Srini Akkaraju, MD, PhD, Managing Partner at Samsara BioCapital, to analyze the prospects for a

Former Investor Who Chose Broadcasting Over Biotech ETFs

Sep 30 2024 11 mins  
Former biotech investor, Brad Loncar has pivoted his career from investing to reporting on the industry. Instead of serving the biotech bubble, he hopes to reach a wide audience with interest in science. Loncar explains why he switched careers and sets out his ambitions for his channel, Biotech TV.

Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?

Aug 29 2024 33 mins  
The hardest parts of drug discovery will be vastly simplified if the mysteries of molecules and proteins can be cracked. That may be beyond human capabilities – but AI is working hard on it. In this episode of RBC’s Pathfinders in Biopharma, Noël Brown is joined by Clarissa Desjardins, CEO of Congruence, and Laksh Aithani, CEO and Co-founder of Charm Therapeutics, to discuss h

Shots-on-Goal Licensing Company Aims for Breakthroughs

Jul 19 2024 13 mins  
A very special breed of animals is helping biotech and pharma companies in the quest for new human therapeutics. CFO Kurt Gustafson joins Pathfinders in Biopharma to explain the technologies behind OmniAb’s business model.

Why Biopharma Needs to Tell Better Stories on Novel Drugs

Jul 11 2024 15 mins  
Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin. He continues his mission to bring new drugs to patients with unmet medical needs. The CEO of Jasper Therapeutics explains his ambitions for his company’s new antibody therapy and for the future of the industry. 

Venture capital velocity: What’s driving renewed momentum in biotech?

Jul 08 2024 35 mins  
In biotech, a recovery is already well underway. Expected interest rate cuts and improving valuations across public and private markets are creating a compelling environment for deals, entrances, exits, and trades to take shape.In this episode, biotech venture capital experts assess the sector’s sharper focus on funding fundamental science, evolving deal structures, including the

Pharma Understands Phase One Data – But Does the Market?

Jun 21 2024 25 mins  
Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara Sullivan, explains the company’s journey to find the right investors, and why she believes the markets still have some learning to do when analyzing data from early-stage studies.

Davern Capital sees GLP-1 Opportunities Beyond Obesity

Jun 14 2024 9 mins  
Davern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but as a former doctor, he also speaks the language of medicine. He explains the fund’s approach and offers insights on hot topics in the current market.

Betting on Healthcare’s Future Hits – and Misses

Jun 10 2024 14 mins  
As a healthcare-focused, market-neutral investor, Vince Aita stays close to new product developments with a view to identifying future successes and failures. At RBC’s Global Healthcare Conference, he offered his insights on everything from the future of obesity innovation to the impact of the IRA.

Innovation and an Aging Population Drive MedTech

Jun 05 2024 16 mins  
The MedTech sector continues to grow in the U.S. as innovation in patient treatments and delivery meets increased demand from an aging population. Medical technology analyst Shagun Singh assesses key data points from the RBC Capital Markets’ Doctor Days events, looking at how the healthcare sector can empower investors to position themselves for future growth.